At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GLSI Greenwich Lifesciences Inc
Trading 12-22 11:29:35 EST
13.47
+0.46
+3.55%
High14.01Low13.29Vol147.75K
Open13.36D1 Closing13.01Amplitude5.51%
Mkt Cap186.65MTradable Cap85.88MTotal Shares13.85M
T/O2.03MT/O Rate2.32%Tradable Shares6.37M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Greenwich Lifesciences Outlines Plans to Expand FLAMINGO-01 Trial Sites, Reduce Costs, Pursue Additional Patent Filings, and Advance Partnering Strategy for GLSI-100
Reuters  ·  12-22 19:00
Greenwich Lifesciences Outlines Plans to Expand FLAMINGO-01 Trial Sites, Reduce Costs, Pursue Additional Patent Filings, and Advance Partnering Strategy for GLSI-100
Greenwich Lifesciences Provides Additional Updates on Flamingo-01 and Corporate Strategy
THOMSON REUTERS  ·  12-22 19:00
Greenwich Lifesciences Provides Additional Updates on Flamingo-01 and Corporate Strategy
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
GlobeNewswire  ·  12-22 19:00
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
Greenwich Lifesciences Inc. held annual shareholder meeting
Reuters  ·  12-19
Greenwich Lifesciences Inc. held annual shareholder meeting
Greenwich Lifesciences Reports 80% Reduction in Breast Cancer Recurrence in FLAMINGO-01 Trial
Reuters  ·  12-15
Greenwich Lifesciences Reports 80% Reduction in Breast Cancer Recurrence in FLAMINGO-01 Trial
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
GlobeNewswire  ·  12-08
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
BRIEF-Greenwich Lifesciences Provides Global Update On Flamingo-01
Reuters  ·  12-03
BRIEF-Greenwich Lifesciences Provides Global Update On Flamingo-01
Greenwich Lifesciences Provides Global Update on Flamingo-01, Screening Over 1,000 Patients to Date
THOMSON REUTERS  ·  12-03
Greenwich Lifesciences Provides Global Update on Flamingo-01, Screening Over 1,000 Patients to Date
Top Executive Makes Bold Move with Major Stock Purchase
TIPRANKS  ·  11-29
Top Executive Makes Bold Move with Major Stock Purchase
Greenwich LifeSciences CEO and CFO Snehal Patel Acquires Common Shares
Reuters  ·  11-28
Greenwich LifeSciences CEO and CFO Snehal Patel Acquires Common Shares
Greenwich Lifesciences CEO and CFO Snehal Patel Reports Acquisition of Common Shares
Reuters  ·  11-12
Greenwich Lifesciences CEO and CFO Snehal Patel Reports Acquisition of Common Shares
Greenwich Lifesciences CEO and CFO Snehal Patel Reports Acquisition of Common Shares
Reuters  ·  11-04
Greenwich Lifesciences CEO and CFO Snehal Patel Reports Acquisition of Common Shares
Greenwich LifeSciences Expands Breast Cancer Trial to Austria
MT Newswires Live  ·  10-09
Greenwich LifeSciences Expands Breast Cancer Trial to Austria
BRIEF-Greenwich lifesciences announces addition of austria to FLAMINGO-01 clinical trial
Reuters  ·  10-09
BRIEF-Greenwich lifesciences announces addition of austria to FLAMINGO-01 clinical trial
Greenwich Lifesciences Announces Addition of Austria to Flamingo-01 Clinical Trial
THOMSON REUTERS  ·  10-09
Greenwich Lifesciences Announces Addition of Austria to Flamingo-01 Clinical Trial
Greenwich Lifesciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
THOMSON REUTERS  ·  10-02
Greenwich Lifesciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
BRIEF-Greenwich Lifesciences Announces Addition Of Portugal To Flamingo-01 Clinical Trial
Reuters  ·  09-30
BRIEF-Greenwich Lifesciences Announces Addition Of Portugal To Flamingo-01 Clinical Trial
Greenwich Lifesciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
THOMSON REUTERS  ·  09-30
Greenwich Lifesciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel's holdings dropped 12% in value as a result of the recent pullback
Simply Wall St.  ·  09-29
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel's holdings dropped 12% in value as a result of the recent pullback
Greenwich LifeSciences expands Phase 3 Flamingo-01 clinical trial to Ireland
TIPRANKS  ·  09-18
Greenwich LifeSciences expands Phase 3 Flamingo-01 clinical trial to Ireland

Introduction

Company Name.
Greenwich Lifesciences Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Issue price:
--